B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma research hub

Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy with Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma

This study is testing a new drug, TL-895, for people with certain types of blood cancers that have come back or not responded to previous treatments. It's looking to see if the drug is safe and how well it helps control the cancer, sometimes in combination with another drug.